Powell Investment Advisors’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Powell Investment Advisors’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-60,000	Closed	-$23K	–	146
2022 Q2	$23K	Buy	+60,000	New	+$42K	0.01%	138
2022 Q1	–	Sell	-64,000	Closed	-$156K	–	142
2021 Q4	$156K	Buy	64,000 +21,000	+49%	+$91.2K	0.09%	108
2021 Q3	$229K	Buy	+43,000	New	+$387K	0.14%	92

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Powell Investment Advisors's CRXT Position: Q3 2022 in Review

Powell Investment Advisors sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 60,000 shares — an estimated $23K sold.

Powell Investment Advisors first reported a position in CRXT in Q3 2021 and held it in 3 quarters. The position peaked at $229K in Q3 2021. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Powell Investment Advisors reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Powell Investment Advisors sold 60,000 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $23K.
Powell Investment Advisors first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
Powell Investment Advisors's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $229K in Q3 2021.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Powell Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.